[HTML][HTML] The antibiotic resistance crisis, with a focus on the United States

E Martens, AL Demain - The Journal of antibiotics, 2017‏ - nature.com
Beginning with the discovery of penicillin by Alexander Fleming in the late 1920s, antibiotics
have revolutionized the field of medicine. They have saved millions of lives each year …

Targeting Energy Metabolism in Mycobacterium tuberculosis, a New Paradigm in Antimycobacterial Drug Discovery

D Bald, C Villellas, P Lu, A Koul - MBio, 2017‏ - journals.asm.org
Drug-resistant mycobacterial infections are a serious global health challenge, leading to
high mortality and socioeconomic burdens in develo** countries worldwide. New …

Turning the respiratory flexibility of Mycobacterium tuberculosis against itself

DA Lamprecht, PM Finin, MA Rahman… - Nature …, 2016‏ - nature.com
Abstract The Mycobacterium tuberculosis (Mtb) electron transport chain (ETC) has received
significant attention as a drug target, however its vulnerability may be affected by its flexibility …

The efflux inhibitor phenylalanine-arginine beta-naphthylamide (PAβN) permeabilizes the outer membrane of gram-negative bacteria

RP Lamers, JF Cavallari, LL Burrows - PloS one, 2013‏ - journals.plos.org
Active efflux of antimicrobial agents is a primary mechanism by which bacterial pathogens
can become multidrug resistant. The combined use of efflux pump inhibitors (EPIs) with …

Collapsing the proton motive force to identify synergistic combinations against Staphylococcus aureus

MA Farha, CP Verschoor, D Bowdish, ED Brown - Chemistry & biology, 2013‏ - cell.com
Pathways of bacterial energy metabolism, such as the proton motive force (PMF), have
largely remained unexplored as drug targets, owing to toxicity concerns. Here, we elaborate …

Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline

MC Cholo, MT Mothiba, B Fourie… - Journal of Antimicrobial …, 2016‏ - academic.oup.com
Abstract Drug-resistant (DR)-TB is the major challenge confronting the global TB control
programme, necessitating treatment with second-line anti-TB drugs, often with limited …

Identification of the bacteriophage nucleus protein interaction network

E Enustun, A Deep, Y Gu, KT Nguyen… - Nature Structural & …, 2023‏ - nature.com
In the arms race between bacteria and bacteriophages (phages), some large-genome
jumbo phages have evolved a protein shell that encloses their replicating genome to protect …

[HTML][HTML] ATP synthase in mycobacteria: special features and implications for a function as drug target

P Lu, H Lill, D Bald - Biochimica et Biophysica Acta (BBA)-Bioenergetics, 2014‏ - Elsevier
ATP synthase is a ubiquitous enzyme that is largely conserved across the kingdoms of life.
This conservation is in accordance with its central role in chemiosmotic energy conversion, a …

Energetics of pathogenic bacteria and opportunities for drug development

GM Cook, C Greening, K Hards, M Berney - Advances in microbial …, 2014‏ - Elsevier
The emergence and spread of drug-resistant pathogens and our inability to develop new
antimicrobials to overcome resistance has inspired scientists to consider new targets for …

[HTML][HTML] Targeting the ATP synthase in bacterial and fungal pathogens: beyond Mycobacterium tuberculosis

M Vestergaard, D Bald, H Ingmer - Journal of Global Antimicrobial …, 2022‏ - Elsevier
The ATP synthase is a multicomponent enzyme that is largely conserved across the
kingdoms of life. In many species the ATP synthase is central in the synthesis of ATP by …